Lyell Immunopharma Inc (LYEL)

Dec 17, 2024

Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Dec 17, 2024

Dec 16, 2024

Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat

Dec 16, 2024

Dec 13, 2024

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance

Dec 13, 2024

Dec 11, 2024

Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia

Dec 11, 2024

Dec 11, 2024

Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India

Dec 11, 2024

Dec 10, 2024

Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan

Dec 10, 2024

Dec 09, 2024

Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com

Dec 09, 2024

Dec 09, 2024

Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Dec 09, 2024

Nov 29, 2024

SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow

Nov 29, 2024

Nov 29, 2024

Lyell Immunopharma Reports Resignation of Board Member - Defense World

Nov 29, 2024

Nov 26, 2024

Lyell Immunopharma Director Hans bishop resigns - Investing.com

Nov 26, 2024

Nov 26, 2024

Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia

Nov 26, 2024

Nov 20, 2024

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN

Nov 20, 2024

Nov 12, 2024

HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Nov 12, 2024

Nov 12, 2024

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga

Nov 12, 2024

Nov 09, 2024

Lyell Immunopharma: Q3 Earnings Snapshot - AOL

Nov 09, 2024

Nov 08, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - The Manila Times

Nov 08, 2024

Nov 08, 2024

Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 06, 2024

Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com

Nov 05, 2024

Nov 03, 2024

Lyell shares down as BofA double downgrades to Sell - MSN

Nov 03, 2024

Nov 03, 2024

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World

Nov 03, 2024

Nov 01, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio South San Francisco, Calif., Oct. 31, 2024 – Lyell Immunopharma, Inc. (NASDAQ: LYEL), a clinical-stage T-cell reprogramming company focusing on next-generation CAR T-cell therapies for solid - Defense World

Nov 01, 2024

Oct 31, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times

Oct 31, 2024

Oct 31, 2024

Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India

Oct 31, 2024

Oct 31, 2024

B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN

Oct 31, 2024

Oct 31, 2024

Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024

Oct 30, 2024

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga

Oct 30, 2024

Oct 30, 2024

Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com South Africa

Oct 30, 2024